RecruitMe Clinical Trial

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
Study of Drug in Patients with Progressive Supranuclear Palsy
Sponsor:AbbVie, Inc.
Enrolling:Male and Female Patients
Minimum Age:40 years old
IRB Number:AAAR2561
U.S. Government ID:NCT02985879
Contact: Evelyn D. Dominguez: 212-305-2371 / edd5@cumc.columbia.edu
Additional Study Information:

This is a study for persons with a diagnosis of Progressive Supranuclear Palsy, involving an experimental treatment.

This study is closed
Investigator
Lawrence Honig, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Evelyn D. Dominguez
Email: edd5@cumc.columbia.edu
Phone: 212-305-2371